S1216, Phase III ADT+TAK-700 vs. ADT+Bicalutamide for Metastatic Prostate Cancer

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2013
The purpose of this study is to compare overall survival in newly diagnosed metastatic prostate cancer patients randomly assigned to androgen deprivation therapy (ADT) + TAK-700 versus ADT + bicalutamide.
Epistemonikos ID: a3f6a2268617ba2943200cde55290b1bbc4a65b5
First added on: Jul 25, 2023